<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00842192</url>
  </required_header>
  <id_info>
    <org_study_id>NN304-3735</org_study_id>
    <nct_id>NCT00842192</nct_id>
  </id_info>
  <brief_title>An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries</brief_title>
  <acronym>BO2NE</acronym>
  <official_title>A Prospective, Multicentre, Multinational, Open Label, Non-controlled, Observational, 24-week Study in Patients Using Oral Anti-Diabetic (OAD) Drugs + Levemir® (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus in Near East Region Countries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Asia. The aim of this observational study is to investigate the
      safety and efficacy of insulin detemir as add-on therapy in type 2 diabetic patients who are
      using oral antidiabetic drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in number of hypoglycaemic events from baseline</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects to reach HbA1c between 6.5 and 7.0%</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability as measured by FPG</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial glycaemic control as measured by PPG</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dose and number of injections</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse drug reactions (ADR)</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2155</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin detemir</intervention_name>
    <description>Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>NN304</other_name>
    <other_name>Levemir®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any subject with type 2 diabetes who is newly diagnosed or treated with OADs only is
        eligible for the study. The selection of the subjects as well as the treatment insulin will
        be at the discretion of the individual physician based on clinical judgement.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  After the physician decision has been made to use insulin detemir therapy, any subject
             with Type 2 diabetes who is treated with any one or more of the oral antidiabetic drug
             (metformin, SU, repaglinide, TZDs) is eligible for the study. The selection of the
             subjects will be at the discretion of the individual physician. Particular attention
             should be paid to the drug interactions that are listed within the product label

        Exclusion Criteria:

          -  Subjects currently being treated with insulin detemir or any other insulin regimen
             including regular(bolus) insulin

          -  Subjects with a hypersensitivity to insulin detemir or to any of the excipients

          -  Women who are pregnant, breast feeding or have the intention of becoming pregnant
             within next 6 months. Women of childbearing potential who are not using adequate
             contraceptive methods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44425</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Amman</city>
        <zip>11844</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Amman</city>
        <zip>11844</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Jordan</country>
    <country>Lebanon</country>
    <country>Pakistan</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2009</study_first_submitted>
  <study_first_submitted_qc>February 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2009</study_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

